Skip Navigation
Skip Website Tools

Contact Info

Email: prpl@mail.cc.nih.gov
Call toll free: 800-411-1222
(TTY 866-411-1010)
Se habla español.
More contact info

Online Screener

Healthy people can help us better understand, treat, and prevent diseases. Complete an online screener if you want to volunteer for a clinical research study.

FACT: People born from 1945 - 1965 are 5 times more likely to be infected with Hepatitis C.  Learn more: http://www.cdc.gov/KnowMoreHepatitis/

NIAID HIV and Emerging Infectious Diseases Program

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Viral Hepatitis Studies

The National Institutes of Health (NIH) houses the nation’s most renowned biomedical research institutions. The following clinical research studies are being conducted by NIAID and the NIH Clinical Center in Bethesda, Maryland:

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected with HIV- HCV

(CONQUER 14-CC-0065)

​You are being asked to participate in this study because you have HIV infection and you have liver disease caused by infection with the hepatitis C virus (HCV). Asunaprevir (ASV) and daclatasvir (DCV) are new oral medications being developed for the treatment of HCV infection. They are still being researched and are not approved by the Food and Drug Administration (FDA). This combination of Asunaprevir (ASV) and daclatasvir (DCV) has never been given to individuals with HIV and HCV infection. The purpose of this study is to determine whether ASV in combination with DCV for 24 weeks can be safe and effective for treating HCV infection in people who also have HIV infection. Volunteer compensation and study medications will be provided.

Evaluation of Clinical, Virologic and Immunologic Factors that Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications

(HCVRES – Protocol #04-I-0086)

Determining how the immune system of some patients is able to control hepatitis C virus (HCV) is felt to be a very important step for designing vaccines and therapies for HCV. Several studies have shown that co-infection with human immunodeficiency virus (HIV) adversely affects liver disease due to HCV. Our laboratory is recruiting patients to further understand the mechanism (s) involved in the interactions between HCV and HIV and how such interactions affect the progression of one another. Patients who are infected with HCV alone or who are also co-infected with both HCV and HIV are being recruited.

A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients

(SYNERGY 13-I-0066)

​GS-7977, GS-5885, GS-9451, and GS-9669 are new medications that are being developed for the treatment of hepatitis C infection. They are still being researched and are not approved by the Food and Drug Administration. The purpose of this study is to determine whether different combinations and treatment schedules of these medications can be safe and effective for treating hepatitis C infection. The manufacturer, Gilead Sciences, Inc., will provide the study drugs. Study medications and volunteer compensation will be provided.

back to top

Last Updated May 07, 2014